Each dot is one of the 13 Generic Drugs stocks, sized by market cap. The median Revenue Growth (1y) (TTM) is 8.0% and the median P/E 31.39. Pinned to the edge: 1 outliers on X and 1 on Y.
Quadrants split at the medians. Hover a dot for its true values; click to open the company. Outliers are more than 3× the interquartile range beyond the quartiles.
| # | Industry | ||||
|---|---|---|---|---|---|
| 1 | ABTAbbott Laboratories | 8.1% | 33.40 | $181.19B | Medical Devices |
| 2 | PFEPfizer | -0.2% | 39.13 | $169.52B | Pharmaceuticals |
| 3 | TEVATeva Pharmaceutical Industries | 4.1% | 65.62 | $46.33B | Generic Drugs |
| 4 | BIIBBiogen | 0.3% | 44.30 | $36.97B | Biotechnology |
| 5 | RDYDr Reddys Laboratories | -10.5% | 31.39 | $11.41B | Generic Drugs |
| 6 | CORTCorcept Therapeutics | 16.0% | 167.43OUT | $9.08B | Pharmaceuticals |
| 7 | AMRXAmneal Pharmaceuticals | 9.3% | 42.52 | $6.69B | Generic Drugs |
| 8 | LQDALiquidia | 2,234%OUT | 28.45 | $3.94B | Pharmaceuticals |
| 9 | OGNOrganon | -2.5% | 17.28 | $3.61B | Pharmaceuticals |
| 10 | ANIPAni Pharmaceuticals | 30.9% | 14.13 | $1.53B | Generic Drugs |
| 11 | AMPHAmphastar Pharmaceuticals | 1.0% | 14.08 | $1.11B | Generic Drugs |
| 12 | ELTPElite Pharmaceuticals | 33.7% | 4.56 | $258.64M | Generic Drugs |
| 13 | ETSTEarth Science Tech | 8.0% | 6.71 | $25.88M | Generic Drugs |
Among Generic Drugs stocks, the largest companies growing revenue faster than the median (8.0%) while trading below the median P/E (31.39) are Liquidia (LQDA), Ani Pharmaceuticals (ANIP), Elite Pharmaceuticals (ELTP) and Earth Science Tech (ETST). A low multiple next to fast growth can be an opportunity or a sign the market doubts the growth will last.
The largest companies with a P/E above the median and revenue growth below it are Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Biogen (BIIB) and Dr Reddys Laboratories (RDY).
The median P/E across the 13 Generic Drugs stocks plotted is 31.39, with the middle half between 14.13 and 42.52.
The median is 8.0%, with the middle half between 0.3% and 16.0%.
The rank correlation (Spearman) is -0.16, a weak negative relationship: companies with a higher Revenue Growth (1y) (TTM) tend to have a lower P/E.
A company whose value lies more than three interquartile ranges beyond the first or third quartile is treated as an outlier. By default it stays on the chart, pinned to the edge as an open marker, and its true value is shown in the tooltip and the table. In this view 1 companies are outliers on Revenue Growth (1y) (TTM) and 1 on P/E. You can switch to percentile clamping, exclude outliers, or plot raw values on a log scale.
Metrics from Business Quant's screener: trailing-twelve-month figures from SEC filings and multiples on the latest close. A company appears once even when it lists more than one share class. A company with a secondary business line in this industry is included unless you choose primary industry only. Nothing on this page is investment advice.